相关实验视频

Updated: Jan 17, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

通过SPRED1提高肺腺癌对免疫治疗剂的敏感性

Chen Wu¹, Lingling Ma¹, Yi Wang¹

¹Department of Science and Education, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, China.

Translational lung cancer research

|September 15, 2025

概括

与芽相关的EVH1域含有1 (SPRED1) 在肺腺癌 (LUAD) 中降低调节,并预测预后不佳. SPRED1增强了编程死亡配体1 (PD-L1) 的表达,改善了LUAD中的免疫治疗灵敏度.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

编程死亡配体1 (PD-L1) 是癌症免疫治疗中的一个关键目标.
与芽相关的EVH1域含有1 (SPRED1) 负面调节MAPK通路并影响PD-L1表达.
在各种癌症类型中,SPRED1表现出抗瘤特性.

研究的目的:

研究SPRED1在肺腺癌 (LUAD) 免疫治疗中的作用.
阐明SPRED1如何影响LUAD对免疫治疗敏感性的机制.
探索新的策略,以提高LUAD的治疗反应.

主要方法:

对SPRED1和LUAD患者预后的生物信息分析.
使用组织染色,西式涂抹和qRT-PCR对SPRED1表达的定量评估.
功能测试包括CCK-8,殖民地形成,伤口愈合和Transwell测试,以评估LUAD细胞行为和免疫治疗反应.

主要成果:

SPRED1表达在LUAD中较低,与预后不佳,N阶段晚期和病理阶段相关.
在LUAD组织中证实了SPRED1的下调.
SPRED1抑制了LUAD细胞迁移和增殖,并增强了对免疫治疗的敏感性.

结论:

在LUAD中,SPRED1被降低调节,并作为一个独立的预后因素.
SPRED1增强了PD-L1的表达,从而提高了LUAD中的免疫治疗灵敏度.

关键词:

肺腺癌 (LUAD) 是一种肺腺癌.与芽相关的EVH1域含有1 (SPRED1)免疫治疗敏感性免疫治疗敏感性编程死亡链条1 (PD-L1) 编程死亡链条1 (PD-L1)

更多相关视频

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.